JAC Advance Access originally published online on September 19, 2006
Journal of Antimicrobial Chemotherapy 2006 58(5):1031-1035; doi:10.1093/jac/dkl385
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sequential treatment with lamivudine and interferon-
monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations
1 Department of Biotechnology, Dalian University of Technology Dalian 116023, Liaoning Province, China 2 No. 6 Hospital of Dalian, Dalian 116001, Liaoning Province, China 3 Jiangsu Oil Field Hospital Shaobo, Jiangdu 225261, Jiangsu Province, China 4 Management School, Shanghai Jiaotong University Shanghai, China
Received 23 April 2006; returned 5 June 2006; revised 16 August 2006; accepted 30 August 2006
*Corresponding author. Tel: +86-411-82718511 3083; Fax: +86-411-82714773; E-mail: zhsh6655{at}sohu.com
Objectives: To assess the efficacy of sequential treatment with lamivudine and interferon-
monotherapies in Chinese patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B.
Methods: One hundred and sixty-two patients with HBeAg-negative chronic hepatitis B were included in this study. Ninety-eight were treated with lamivudine alone (100 mg per day) for 48 weeks (group B). Sixty-four were treated with lamivudine alone (100 mg per day) for 20 weeks, then combined with interferon--2b (5 million units three times per week) for 4 weeks and then treated for another 24 weeks with interferon--2b alone (5 million units three times per week) (group A). All patients were followed for an additional 24 weeks.
Results: After 48 weeks of treatment, the percentage of patients with normalization of alanine aminotransferase (ALT) levels or hepatitis B virus (HBV) DNA levels below 1000 copies/mL was not significantly different between the lamivudine monotherapy group (55.10% and 55.10%, respectively) and the sequential treatment group (59.36% and 56.25%, respectively). The percentage of patients with normalized ALT levels was significantly higher in group A (53%) than in group B (36%) at week 72 (P < 0.05). The percentage of patients with lamivudine-resistant mutations was significantly higher with lamivudine monotherapy (22.45%) than with sequential therapy (P < 0.05).
Conclusions: Sequential treatment of chronic hepatitis B with lamivudine and interferon- monotherapies is as effective as lamivudine-alone treatment in Chinese patients. However, sequential treatment can significantly suppress the emergence of lamivudine-resistant mutations.
Keywords: chronic hepatitis B , hepatitis B virus , HBV , YMDD
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. A. Shamliyan, R. MacDonald, A. Shaukat, B. C. Taylor, J.-M. Yuan, J. R. Johnson, J. Tacklind, I. Rutks, R. L. Kane, and T. J. Wilt Antiviral Therapy for Adults With Chronic Hepatitis B: A Systematic Review for a National Institutes of Health Consensus Development Conference Ann Intern Med, January 20, 2009; 150(2): 111 - 124. [Abstract] [Full Text] [PDF]
|
|